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Cancer therapyGenomic DNA is constantly challenged from endogenous as well as exogenous sources. The DNA
damage response (DDR) mechanism has evolved to combat these challenges and ensure genomic
integrity. In this review, we will focus on repair of DNA double-strand breaks (DSB) by homologous
recombination and the role of several nucleases and other recombination factors as suitable targets
for cancer therapy. Their inactivation as well as overexpression have been shown to sensitize cancer
cells by increasing toxicity to DNA-damaging agents and radiation or to be responsible for resistance
of cancer cells. These factors can also be used in targeted cancer therapy by taking advantage of
speciﬁc genetic abnormalities of cancer cells that are not present in normal cells and that result
in cancer cell lethality.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Both endogenous as well as exogenous insults are constantly
challenging our DNA, the integrity of which is essential for genome
stability as well as carcinogenesis. Endogenous sources include
reactive oxygen species produced during cell metabolism or
replication of damaged DNA template. Exogenous factors include
chemotherapeutic agents and ionizing radiation. Among the most
toxic types of damage are dsDNA breaks. Two major pathways
have evolved for their repair: non-homologous end joining (NHEJ)
and homologous recombination (HR) (Fig. 1). During NHEJ, the
ends of DNA are directly joined with the help of KU70/KU80 com-
plex, which protects them from degradation and recruits DNA
ligase IV and its accessory factor XRCC4 for their ligation. Recently,
a third alternative, microhomology-mediated end joining (MMEJ),
was described. This requires a greater extent of ends resection in
as much as microhomology (<10 nt) demands that the ends be
annealed. That is in contrast to classical NHEJ, where up to 3 nt
can be used [1–3]. For more detailed description, see the more
extensive reviews regarding NHEJ [4,5]. These mechanisms are
error-prone, however, as they frequently result in loss of genetic
information.On the other hand, HR constitutes an error-free pathway that
requires undamaged homologous sequence on a sister chromatid
from which the information is copied (Fig. 1). The HR mechanism
can be separated into three steps: pre-synapsis, synapsis and
post-synapsis. In the ﬁrst step, the MRE11/RAD50/NBS1 complex
together with CtIP is required for recognition of the ends, damage
signaling, and to initiate end resection at both sides of the double-
strand break (DSB) [6]. Two redundant pathways are required for
long resection to produce a 30-overhang. One depends on EXO1
nuclease and the other involves the activity of DNA2 together with
the BLM/TOP3/RMI1 complex [7,8]. The resulting 30-overhang is
protected by RPA and serves also as a sensor for DNA damage
checkpoint activation [9]. Nevertheless, the RAD51 recombinase
needs to obtain access to DNA in order to form nucleoprotein
ﬁlament capable of homology search. Therefore, recombination
mediators, including BRCA2 and RAD51 paralogues, are required
for loading RAD51 onto RPA-coated ssDNA and stabilizing the
ﬁlament. During synapsis, the RAD51 ﬁlament searches for a
homologous sequence, resulting in formation of a stable intermedi-
ate known as a D-loop with the 30-end of the invading strand
serving as a primer for DNA repair synthesis (Fig. 1). Within
post-synapsis, the intact chromosome is restored. This constitutes
the most complex step, however, as several mechanistically differ-
ent scenarios can arise, namely: synthesis-dependent strand
annealing (SDSA), classical DSB repair (DSBR), and break-induced
replication (BIR) (Fig. 1). During SDSA, the extended D-loop is dis-
placed by the action of helicase. There then follows annealing with
D-loop
NHEJ / MMEJ
SSA
DSB
dHJ
gene conversion gene conversion crossoverhalf crossover gene conversion
DSBRSDSABIR
MRE11/RAD50/NBS1
EXO1, DNA2, BLM
RAD51
BLM
RAD52
MRE11
XPF/ERCC1
XPF/ERCC1
dissolution
MUS81/EME1, SLX1/SLX4, GEN1, MLH1, EXO1
Fig. 1. Model of pathways involved in repair of double-strand breaks. Possible targets for therapeutic intervention are highlighted in green
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synthesis and ligation. Here, Mus81/EME1 is believed to cleave
possible 30-ﬂaps generated as a consequence of annealing over-
synthesized invading strand. In DSBR, the extended D-loop is not
displaced (which is in contrast to SDSA), but rather it is stabilized
by BRCA2- and RAD52-mediated capturing of the second end of the
break. After a second round of DNA synthesis, a double Holliday
junction (HJ) is formed. From here, either dissolution by BLM/
TOP3/RMI1 or resolution by the coordinated action of several nuc-
leases (including SLX1-SLX4, GEN1, XPF/ERCC1 and MUS81/EME1)
restores the integrity of the genome. Finally, BIR operates via a
pathway where one end of the DSB is lost and only the other end
is used for repair. Here, the D-loop is converted to a replication
fork-like structure that ensuring synthesis along the chromosomal
arm. Again, most of the nucleases have been shown to be involved
in BIR. Not only are frequent gross chromosomal rearrangements
and loss of heterozygosity associated with this pathway, however,
but the synthesis also is more mutagenic compared to normal rep-
lication. Finally, when extension resection of DSB reveals regions of
homology, single strand annealing (SSA) pathway comes into play.
In contrast to HR, the ends are healed using the same DNA mole-
cule containing the break. RAD52 anneals the complementary
strands of the homologous region, thereby generating 30-tails that
are processed by XPF-ERCC1 nuclease, and this is followed by DNA
synthesis and ligation. Several recent reviews provide more
detailed description [10–14].
We will describe below some of the promising targets of HR or
DDR pathways for chemical biology or therapeutic intervention
while speciﬁcally focusing on nucleases. As already noted above,
various nucleases participating in HR are responsible for the
processing end of DSBs and resolution of DNA replication orrecombination intermediates (Fig. 1). However, they often play
redundant and overlapping roles in other DNA repair pathways.
Mutations in some of them are directly associated with diseases
or they show defects in DNA repair, accumulation of damage,
and greater risk of genome instability (thereby creating a predispo-
sition to cancer). On the other hand, DNA repair enzymes, includ-
ing nucleases, are also commonly upregulated in some cancer
types to ensure efﬁcient repair of DNA damage caused by chemo-
or radiotherapy, and this can lead to drug resistance. Down-
regulation or identiﬁcation of suitable nuclease inhibitors can
potentiate the effects of current anti-cancer therapies and provide
new tools in targeted cancer therapy, especially in the light of
synthetic lethal approaches. To achieve this, detailed understand-
ing of various repair mechanisms, their inhibitors, interaction
partners, associated diseases, localization, expression levels and
post-translational modiﬁcations is required.
1.1. MUS81
MUS81 is a member of the XFP family of endonucleases. It is
evolutionarily conserved and forms a complex with a non-catalytic
subunit – either EME1 or EME2 (which for simplicity’s sake we will
refer to as MUS81 complex) – that differs among species (Mms4 in
budding yeast; Eme1 in ﬁssion yeast). Despite having little homol-
ogy, these subunits have been shown to be involved in DNA bind-
ing and required for enzymatic activity of the complex [15–19].
Puriﬁed MUS81 complex has the highest afﬁnity for DNA struc-
tures. It has an exposed 50-end near the DNA junction, including a
30-ﬂap, nicked Holliday junction (nHJ) and forks (Table 1). It intro-
duces a nick at the duplex 3–7 nt away from the junction point
[16,20–23]. MUS81’s activity, together with increased expression
Table 1
Summary of substrate speciﬁcities of selected nucleases and their role in various pathways.
Nuclease Substrates for endo-activity Substrates for exo-activity Pathways
Mus81-EME1 30-ﬂap, nHJ, mHJ, fork, D-loop RF restart, HR, ICLR, TM
XPF-ERCC1 30-ﬂap, bubble, D-loop, G-tail NER, HR, ICLR, NHEJ, MMEJ, SSA, TM
SLX1-SLX4 50-ﬂap, HJ HR, ICLR, SSA, RF restart, BER, NER, TM
GEN1 50-ﬂap, HJ HR
FEN1 50-ﬂap, double ﬂap 50–30 on nicked dsDNA BER, OFM, TM
MRE11 50-ﬂap 30–50 on dsDNA HR, NHEJ, MMEJ, TM
EXO1 50-ﬂap 50–30 , 30–50 on dsDNA HR, SSA, MMR, NER, OFM, TM
DNA2 50-ﬂap OFM, HR, SSA, TM
RF restart – replication fork restart, HR – homologous recombination, ICLR – interstrand DNA crosslink repair, TM – telomere maintenance, NER – nucleotide excision repair,
NHEJ – non-homologous end joining, SSA – single strand annealing, BER – base excision repair, MMEJ – microhomology mediated end joining, OFM – Okazaki fragment
maturation.
Table 2
Expression levels of selected HR factors identiﬁed in primary cancers.
Nuclease Increased expression Decreased expression
MUS81 Gastric, colorectal,
hepatic cancer
ERCC1 Ovarian, colorectal, gastric, head and
neck, non-small-cell lung cancer
Gastric, colorectal,
non-small-cell lung
cancer
FEN1 Testes, lung, brain, breast, kidney,
pancreatic, colon cancer
Lung, prostate,
gastrointestinal
cancer
MRE11 Ovarian, breast,
colorectal cancer
RAD50 breast cancer
NBS1 Neck and head cancer, melanoma Breast, colorectal
cancer, melanoma
EXO1 Atypical HNPCC
DNA2 Breast, pancreatic, ovarian cancer,
pancreatic ductal adenocarcinoma
RAD51 Breast, pancreatic, head and neck,
non-small-cell lung cancer
Colorectal, breast
cancer
RAD52 Colorectal cancer
Expression conﬁrmed by mRNA/protein level measurements from cancer patients.
2448 Z. Bartosova, L. Krejci / FEBS Letters 588 (2014) 2446–2456during S phase and the peak in G2 [24], suggests its role in process-
ing replication and recombination intermediates. During S phase, it
is responsible for cleavage of collapsed replication fork induced by
DNA damaging agents [25–28]. Interestingly, EME1/Mms4 is
tightly regulated during S phase in a cell cycle dependent manner
to prevent untimely cleavage of replication forks [29–31].
DSBs produced as a consequence of cleaved and/or collapsed
replication forks are substrates for homologous recombination to
allow replication fork restart [27]. MUS81 is not involved only in
generating a substrate for HR, however, but is also required for
processing of recombination intermediates. MUS81 complex is tar-
geted by RAD54 to the downstream DNA intermediates, which dra-
matically stimulate its nuclease activity, and it has been shown to
be involved in the SDSA sub-pathway of HR to provide an alterna-
tive mechanism for BLM-dependent dissolution of HJ [25,32–34].
Similarly, deletion of MUS81 results in severe meiotic defects con-
sistent with a failure to process recombination intermediates
[15,22]. Because its phenotypes in yeast could be rescued by
expression of RusA, its function as a Holliday junction resolvase
has been suggested by [15]. Nevertheless, nicked Holliday junc-
tions and D-loops are preferred substrates in vitro. In addition,
MUS81 cleaves the substrates asymmetrically, which is in contrast
to typical resolvases, and this results in nicks that are not directly
ligatable [35,36]. Recently, SLX1-SLX4 and MUS81-EME1 have
been shown to cooperate in HJ resolution, with the SLX complex
generating the initial nick and thus creating a more suitable sub-
strate for MUS81-EME1 counter cleavage [37,38].
MUS81-deﬁcient cells exhibit proliferation defects and accumu-
late various chromosomal aberrations [39,40]. Haploinsufﬁciency
of MUS81 has been shown to result in chromosomal abnormalities
and increased sensitivity to crosslinking agents [41,42], thus indi-
cating that already a single copy of MUS81 can result in genomic
instability. Accordingly, decreased levels of MUS81 expression
have been found in hepatic metastasis and correlated with poor
cancer prognosis [43] (Table 2). A role for MUS81 in tumorigenesis
is further supported by evidence of a synergistic effect with inacti-
vation of p53 and, on the other hand, suppression by inactivating
CHK2 [44]. This all together suggests MUS81 to be a potential tar-
get for cancer therapy.
1.2. XPF-ERCC1
XPF-ERCC1 (yeast homolog Rad1-Rad10) is a structure-speciﬁc
endonuclease participating in multiple repair pathways, including
nucleotide excision repair (NER), interstrand crosslink repair
(ICLR), HR and NHEJ. XPF protein forms a stable heterodimer with
a non-catalytic subunit, ERCC1, which is essential for its endonu-
clease activity and also ensures binding to DNA and other proteins.
Preferred DNA structures are splayed-arm, bubble, stem-loop and
D-loop structures (Table 1). Cuts are introduced in duplex DNA ata 50-side of a ssDNA/dsDNA junction, preferably with the 50-end
further away [45–51].
The XPF complex plays an essential role in NER, as correspond-
ing mutants show sensitivity to UV lesions [52] and it is responsi-
ble for a 50 incision of a bubble DNA lesion generated during NER.
XPG is responsible for a corresponding 30 cleavage that results in a
release of ssDNA oligonucleotide containing the lesion. The newly
formed gap is subsequently ﬁlled by a DNA polymerase and ligated
[49,53–55]. In contrast to other NER factors, the XPF is hypersensi-
tive to ICL. This suggests its more speciﬁc role in crosslink repair
[56]. Although the precise mechanism of ICL repair is not clear, it
employs XPF in the incision step due to its ability to cleave the
DNA on either side of the ICL [57]. In addition to ICL, XPF complex
is also involved in HR and NHEJ, as mutations in XPF-ERCC1 cause
sensitivity to DSBs [58–61]. XPF-ERCC1 processes 30-non-homolo-
gous single-strand tails during RAD52-mediated SSA and in MMEJ
[59,58,62,60,63]. XPF activity is also required during meiotic
recombination to process recombination intermediates [64,65].
While in Drosophila this might constitute the major pathway in
HJ processing [66], in other organisms its activity is more redun-
dant and linked with other nucleases. Indeed, such coordination
has been reported for human MUS81 and XPF complexes [67,68],
thus indicating a high level of complexity to ensure resolution of
various intermediates.
Mutations in XPF protein have been identiﬁed in patients with
Xeroderma pigmentosum (XP) and a progeroid syndrome (XFE).
While XP patients fail to repair DNA damage caused by UV, the
XFE patients display premature aging syndromes [69,70], thus
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ERCC1 was found in a complex with telomeric protein TRF2, which
protects the chromosome ends from degradation. Moreover,
ERCC1-defective cells show telomere deletions and formation of
T-loop structures as a consequence of processing telomeric recom-
bination intermediates [71]. A number of various cancers show a
link between increased expression of ERCC1 and poor response
to platinum-based therapy [72–74] (Table 2). Accordingly, while
ERCC1-proﬁcent xenografts were shown to be resistant to cisplatin,
ERCC1-deﬁcient ones were completely cured [75]. Together with
its defensive role in cancer cells by means of repairing the damage
caused to those cells by chemotherapeutics, this makes XPF a valu-
able target for sensitization and chemoresistance of cancer cells. It
also should be noted that not only inhibition of nuclease activity
but also helicase-like domain as well as interaction with RPA and
XPA proteins may present attractive targets for drug discovery
programs.
1.3. SLX4 (FANCP)
SLX4 (FANCP) is a structure-speciﬁc subunit that serves as a
scaffold for such other structure-speciﬁc endonucleases as
MUS81-EME1, XPF-ERCC1 and SLX1 [45,48,50]. Together these
form a multiprotein complex responsible for repair of damaged
DNA and are essential for replication fork restart and ICL repair.
The SLX1-SLX4 complex has a preference for branched structures
like 50-ﬂaps, but, in contrast to the fungal protein, the human
complex can also cleave static and mobile HJs and thus has been
suggested to function as a HJ resolvase [50,48,76,45,77] (Table 1).
It introduces symmetrical cuts in duplex DNA near junctions with
ssDNA, resulting in nicked duplex products which are readily ligat-
able [45,48,50].
SLX4 enhances endonuclease activity of associated nucleases
XPF-ERCC1, MUS81-EME1 and SLX1, and it plays a crucial role in
ICL repair [48,50,45]. An interaction with XPF-ERCC1 promotes
cleavage of bubble structures during processing of UV-damage in
NER and is also required during the SSA pathway of DSB repair
[78,79]. Similarly, the interaction with MUS81-EME1 leads to
cooperation in HJ resolution [38,37]. SLX4 is involved in telomere
maintenance, as it associates with TRF2 and localizes to the
telomeric regions; moreover, the RTEL1-deﬁcient cells show
SLX4-mediated replication stalling at telomeres and their cleavage
generating telomeric circles [50,80,81].
The importance of SLX4 in ICL repair and genomic stability is
underscored by the identiﬁcation of biallelic mutations in SLX4
in patients with Fanconi anemia complementation group P and
hereditary breast cancer [82–84]. While inhibition of SLX4 should
sensitize the cells to DNA crosslinking agents, as reported for
SLX4-deﬁcient cells [48,85,84], the inhibition of its mediated inter-
actions should have speciﬁc and/or broad effect on various repair
pathways.
1.4. GEN1
GEN1 (yeast Yen1) belongs to the Rad2/XPG family of structure-
speciﬁc endonucleases [86]. GEN1 is unique for its activity in
resolving HJs, which occurs through its ability to dimerize on HJs
and cleave these symmetrically to produce two nicked duplexes
that can be easily ligated [87] (Table 1). An absence of human
GEN1 leads to defects in HR and accumulation of DNA damage
[88]. Its co-depletion with MUS81 or SLX4 in BLM-deﬁcient cells
results in severe chromosomal instability [89], thus indicating a
role of GEN1 in HJ resolution in vivo. The functional overlap with
Mus81, Slx4 and Rad1 nucleases also has been suggested to play
an important role in processing recombination intermediates in
yeast [86,90–92]. Cytological and cell cycle analysis supports theidea that GEN1 could be the last resort in resolving unprocessed
HJ to ensure genetic stability, as GEN1 gains access to DNA at the
initiation of mitosis [88,93].
The synthetic lethality of cells lacking GEN1 and Fanconi ane-
mia-linked SLX4 [37] further indicate its requirement for process-
ing HJ in vivo and make this a good candidate for therapeutic
intervention. Finally, GEN1 mutations predicted to affect nuclease
activity were identiﬁed in a cohort of breast cancer patients, thus
indicating possible association with carcinogenesis [86]. More
studies are required, however, in order to conﬁrm this observation.
1.5. FEN1
FEN1 (yeast Rad27) has several essential roles during DNA rep-
lication and repair [94]. It is a member of the Rad2/XPG family and
has 50–30exonuclease, gap endonuclease and RNaseH activities
[95,96]. These different modes of hydrolysis share a predominant
incision 1 nt into the downstream dsDNA with minor cleavage at
50 or 30 of the site [97]. While, double-ﬂap DNA is the most pre-
ferred substrate for FEN1 in vivo, a wide range of substrates is
hydrolyzed by FEN1 using the same active center (Table 1). This
suggests differences in the manner of FEN1’s binding to various
DNA [98–100].
Removal of 50-ﬂap containing RNA primer is crucial for Okazaki
fragment maturation during lagging strand DNA synthesis [97].
This has been validated in vivo, as FEN1-deﬁcent mice demonstrate
defects in DNA replication, cell proliferation and embryonic lethal-
ity [101–103]. The FEN1 activity is also required during long-patch
BER (LP-BER), where a long ﬂap is formed and serves as a substrate
for FEN1 [104]. Concerted action of FEN1 activities is also required
for apoptotic fragmentation and resolution of structures derived
from trinucleotide repeats (TNRs). The role of FEN1 in apoptotic
DNA fragmentation was suggested based on a cell death phenotype
similar to endonuclease G-mediated apoptosis that is observed in
the case of FEN1 deﬁciency [103]. FEN1 also certainly contributes
to TNR stability, regardless of whether it is mediated directly or
as part of redundant pathways [104–107]. Since TNR instability
is observed in many neurodegenerative and neuromuscular dis-
eases, including Huntington disease [108], FEN1 has been sug-
gested to play a role in their development [109]. These ﬁndings
are contradictory, however, and this needs to be further character-
ized. FEN1 is also implicated in other DNA metabolic pathways,
including rescue of stalled replication forks, as well as stability
of minisatellites, telomeres and other repetitive sequences [110–
114]. Accordingly, depletion of FEN1 results in telomere dysfunc-
tion and end-to-end fusions in ALT-positive cancer cells and MEFs
[113,115,116].
The multifaceted activities of FEN1 suggest its essential role in
genomic stability and cancer predisposition. Accordingly, in
knockout mice it is embryonic lethal and its combination with
APC results in cancer development [101,117]. Furthermore, nucle-
ase-deﬁcient mice show an increased mutator phenotype, defects
in apoptosis and susceptibility to cancers [102,103]. Two germline
mutations resulting in lowered FEN1 expression are associ-
ated with increased lung and gastrointestinal cancers [118,119]
(Table 2). In Fanconi anemia, FEN1 haploinsufﬁciency supports
cancer cell proliferation and tumor progression [101]. On the other
hand, once malignant transformation has occurred, FEN1 overex-
pression confers a growth advantage in many types of cancer
[120,121]. Despite risks to cancer-prone patients, inhibition of
FEN1 offers a potent target for use in chemotherapies, and espe-
cially in ones to which resistance is developing. Furthermore,
FEN1 inhibitors can be used in targeting HR-deﬁcient cancers, as
FEN1 mutations accumulate damage that is processed by HR
[122]. Since the multifaceted role of FEN1 requires several regula-
tory modes, including speciﬁc protein interactions, localization,
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can be targeted therapeutically.
1.6. MRE11
MRE11 functions in a complex with RAD50 and NBS1, referred
to collectively as the MRN complex. This complex has multiple
roles in repair of DSBs via HR, NHEJ and MMEJ, as it is responsible
for sensing the DSBs, activating the DNA damage checkpoint,
tethering the ends, evicting nucleosomes in the vicinity of the
break, and initiating end resection (for a review see [123]). The
essentiality of any of the components of the MRN complex for
the cell is underlined by their embryonic lethality in mice
[124–126]. MRE11 possesses 30–50 exonuclease activity and ssDNA
endonuclease activity with preference for blunt ends and branched
substrates such as 50-overhangs [127]. Interestingly, structural
integrity of the complex is more important for the end resection
than for its nuclease activity. MRE11’s nuclease activity together
with NBS1 is nevertheless required for MMEJ, and it also uses its
endonuclease activity to cleave a covalently bound SPO11 at the
50-ends of the DNA after DSB formation during meiosis to initiate
their resection [128–131]. In addition, the MRN complex localizes
to the telomeres and regulates telomeric length either by recruit-
ment of the telomerase RNA subunit or as a sensor of damaged
telomeres promoting ATM activation and alternative lengthening
of telomeres [132–134]. The MRN-mediated end resection and uti-
lization of both HR and NHEJ pathways is promoted by CtIP protein
[135–137]. CtIP has recently been shown to possess nuclease activ-
ity required for processing DNA adducts or secondary structures at
the sites of breaks [138,139], making it also possible target for
chemical intervention.
Germline mutations of MRE11, NBS1 and RAD50 cause ataxia-
telangiectasia-like disease (ATLD), Nijmegen breakage syndrome
(NBS) and NBS-like disorder (NBSLD), respectively. ATLD and
NBSLD have similar features as does ataxia-telangiectasia (AT),
caused by mutations in the ATM gene, which include hypersensi-
tivity to DSB-inducing agents, chromosome fragility, DNA dam-
age-dependent cell-cycle arrest and high predisposition to cancer
[140–144]. Mutations in CtIP have been identiﬁed as causal in
the Seckel and Jawad syndromes and have demonstrated defects
in processing DNA damage and ATR activation [145]. Moreover,
impaired expression of MRE11 is associated with some cancers
and MRE11 depletion sensitizes these to poly(ADP-ribose) poly-
merase (PARP) inhibition [146–149] (Table 2). Together with the
MRN complex’s central role in HR and genome stability, these data
highlight MRE11 and its partners as constituting a valuable phar-
macological target. Indeed, the ﬁrst described MRE11 inhibitors
(mirin and telomelysin) have been conﬁrmed in preclinical studies
to have potential as sensitizers of cancer cells [150–152]. In
addition, MRE11-deﬁcient cells are also sensitive to topoisomerase
poisons [153], thus suggesting a role for MRN in removal of TOP1/
TOP2-DNA intermediates and in stimulating an effect of topo
inhibitors. Indeed, triapine (RNR inhibitor) was recently shown to
block MRN/CtIP-mediated HR and sensitize ovarian cancer cells
to PARP and topo inhibitors [154,155]. Further work is required,
however, to potentiate MRN inhibitors for clinical trials.
1.7. EXO1
EXO1 belongs to the RAD2/XPG nuclease family possessing 50–30
exonuclease, 50-overhang endonuclease and RNase H activities
(Table 1). It participates in several genome stability pathways,
including MMR, DSB repair, and telomere maintenance. In MMR,
EXO1 is involved in the 50 and 30 directed excision of DNA
mismatches [156,157]. A nuclease-independent and more struc-
tural scaffold-like role of EXO1 in MMR has also been suggestedin yeast [158], but this needs to be further analyzed. During DSB
repair, EXO1 is involved in long resection of DNA ends generating
30-overhangs required for HR [7,159]. During NER, EXO1 insures
gap enlargement, which is a signal for an ATR-mediated DNA
damage response [160,161]. At telomeres, EXO1 promotes telo-
meric recombination by extensive end resection of G-rich strands
and genetic instability in telomerase-deﬁcient cells [162–164].
Such instability, together with involvement in DNA repair
pathways, makes EXO1 a logical target for mutation during
tumorigenesis.
It has been suggested that EXO1 contributes to non-polyposis
colorectal cancer (HNPCC) and sporadic colorectal cancers (CRC)
(Table 2). While missense mutations in EXO1 have been described
in patients with atypical HNPCC [165], the role in suppressing CRC
remains unclear. Nevertheless, EXO1-deﬁcient mice show reduced
survival, higher mutation rates and increased susceptibility to gen-
erate lymphomas [166]. Several studies in yeast point to a possible
multi-mutation hypothesis, where a weaker mutation phenotype
of EXO1 might be combined with other mutator alleles to result
in pathogenesis [158,167]. On the other hand, overexpression of
EXO1 may also increase genetic instability and provide an advan-
tage for cancer’s progression, as suggested by loss of mutant allele
in 12 of 13 atypical HNPCC patients [168]. For more details, see
also [169,170].1.8. DNA2
DNA2 is a conserved helicase/nuclease contributing to DNA rep-
lication and DSB repair. It is an ssDNA-dependent ATPase possess-
ing weak 50–30 helicase activity. The helicase activity is attenuated
by its own endonuclease activity [171]. During lagging strand syn-
thesis, DNA2 interacts with FEN1, where it cleaves long 50-ﬂaps to
provide a suitable substrate for FEN1 [172]. Within DSB repair,
DNA2 is one of the nucleases involved in long resection by process-
ing DNA ends into 30-overhangs together with BLM/TOP3/RMI1
complex [173,8].
In several cancer cells, DNA2 expression is signiﬁcantly
increased and facilitates massive DNA repair by HR [174], thus
providing a possible advantage toward survival in cases of replica-
tion-associated stress (Table 1). Accordingly, depletion of DNA2
sensitizes normal cells but rescues the sensitivity of FANCD2 cells
to cisplatin [175] and thus has possible implications in therapy of
FA patients. A high-throughput screen in Saccharomyces cerevisiae
has revealed that most replication and chromatin dynamics pro-
teins are synthetically lethal with DNA2 [176], making this,
together with its role in genomic stability, a suitable biomarker
as well as a target for chemical intervention.2. Other HR-related targets for pharmacological inhibition
2.1. Checkpoint kinases
Checkpoint kinases in DNA damage response present, in parallel
to individual DNA repair pathways, a main mechanism that senses
DNA damage and orchestrates appropriate responses. DNA damage
results in an induction of cell-cycle arrest allowing sufﬁcient time
for efﬁcient DNA repair. ATM and ATR play central roles in the DDR
pathway by controlling the checkpoint via other downstream
effectors (CHK1, CHK2, p53, BRCA1, etc.). Both activation and
deactivation of the DNA damage response have been observed in
cancers, and both present important condition factors in current
and future clinical trials. The roles of these kinases in tumorigene-
sis and their pharmacological inhibition has been described
extensively elsewhere and will not be included in this review
[177–179].
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RAD51 is one of the key factors in HR and genomic stability. Its
deﬁciency results in early embryonic lethality, and mutations in
RAD51 have been associated with increased risk of breast and colo-
rectal cancers [180–182]. Increased expression, on the other hand,
also has been identiﬁed in a wide range of cancers, thus suggesting
a possible mechanism for resistance [183–186] (Table 2). In addi-
tion, RAD51 paralogues may also constitute potent targets, espe-
cially as RAD51C was recently linked with Fanconi anemia and
identiﬁed as a novel breast cancer susceptibility gene [187,188].
Recently developed RAD51 inhibitors as well as inhibitors of onco-
gene tyrosine kinases [189–191] are expected to sensitize cancer
cells to DNA damage.
2.3. RAD52
RAD52 forms an oligomeric ring, binding both ss- as well as
dsDNA and catalyzing the annealing of complementary strands
during SSA, an alternative pathway to BRCA2-mediated HR. Recent
discovery of synthetic lethality of RAD52- and BRCA2-deﬁcent
cells [192] indicates that RAD52 represents an essential backup
pathway for HR and thus is a very interesting target for BRCA-
associated tumors.
2.4. RecQ
RecQ helicases also represent very promising targets for anti-
cancer therapy through DNA repair inhibition. They function in
multiple cell processes such as DNA replication, transcription,
DNA repair, telomere maintenance and DNA damage signaling
[193–196]. In humans, ﬁve RecQ homologs (RECQL1, WRN, BLM,
RECQL4, RECQL5) have been identiﬁed. Three of these are associ-
ated with syndromes featuring genome instability, premature
aging and cancer predisposition, namely Bloom (mutations in the
BLM gene), Werner (mutations in the WRN gene), Rothmund–
Thomson, RAPADILINO, and Baller–Gerold syndromes (mutations
in the RECQL4 gene) [197–201]. For more details on targeting heli-
case in cancer therapy, see [202].
3. Inhibitors
Inhibition of a gene of interest can be achieved by its downreg-
ulation or alternatively through small chemical compounds. Use of
inhibitors may be a great advantage since proteins function in mul-
tiple pathways and their complete deletion could negatively affect
the entire cell’s metabolism. Medicinal chemistry programs could
provide inhibitors of speciﬁc enzymatic activity, interaction or
localization to block a certain repair pathway while leaving other
functions intact.
However, identiﬁcation of effective small molecule inhibitors is
hindered by the speciﬁcities of cancer cells. Cancer cells have a sig-
niﬁcantly different metabolism than do normal cells and can utilize
alternative pathways to cope with treatment, thereby resulting in
drug resistances. This can be achieved by mutating a speciﬁc target
of chemotherapeutic intervention, thus making it insensitive to the
drug [203]. Similarly, epigenetics have been suggested to play a
leading role in creating resistance to cisplatin [204]. Another pos-
sibility is re-activation of a blocked signal pathway by a gain-
of-function mutation in downstream effectors, although upstream
hyperactivation also has been observed [205]. In addition, multi-
drug resistance-associated proteins greatly contradict cancer
treatment simply by excluding foreign compounds from the cell
through increased efﬂux achieved via overexpression of ABC trans-
porters [206]. Alternatively, enzymatic deactivation of the drug byglutation-S-transferase or decreased membrane permeability
can result in multidrug resistance [207]. Cancer cells are also capa-
ble of inhibiting apoptosis, thus making treatment with DNA-
damaging agents and DNA-repair inhibitors ineffective [208,209],
unless an excessive amount of damage leads to mitotic catastrophe
due to a loss of essential genetic material. Another factor that can
impede success of DNA repair inhibitors is selectivity to tumors.
This could mean that unless these inhibitors are selectively deliv-
ered to cancer cells they may cause adverse defects also to normal
cells. Nevertheless, recent developments in drug delivery, includ-
ing nanomedicine and targeted nano-sized carriers, could have
enormous effects on therapy [210].
Another complication is the treatment of patients with germ-
line syndromes, as all the cells will be sensitive to damaging
agents. This is the case mainly in homozygous mutations, but also
heterozygous cells show haploinsufﬁciency. For example, patients
with Fanconi anemia are hypersensitive to crosslinking agents
and these drugs must be omitted in therapy [211]. Moreover,
tumors are comprised of a population of both dividing and dor-
mant cells, with highly proliferating cells oriented on the surface
of the tumor. Hence, drugs causing replication blocks are not effec-
tive for eliminating the whole tumor and non-replicating cancer
cells can also show different capacities for repair [212]. Finally,
numerous difﬁculties arise in individuals and highly speciﬁc
‘‘personalized’’ cancer therapy may be required that combines a
mechanistic understanding of cancer’s progression and its patho-
genesis with the development of targeted drugs that are stratiﬁed
by genetic characteristics and individualized drug administration.
Despite all these complications, there are positive results that
promise further success and better understanding in the treatment
of cancer and of biological mechanisms generally.
4. Synthetic lethality (SL)
The concept of synthetic lethality or sickness (SLS) represents
one of the most promising perspectives for cancer treatment in
the future. The SLS phenotype requires two mutations. Each of
these alone has no effect on cell viability, but when they are com-
bined this leads to slow growth or cell death. If either of the two
SLS partners is cancer-speciﬁc, then inactivation of the second gene
by a drug-mediated inhibition will provide highly effective and
selective killing of cancer cells without toxic effect to the normal
cells. Since several cancers are defective in DDR and DNA repair
pathways, use of speciﬁc repair inhibitors can take full advantage
of this concept. Regarding HR, this approach was pioneered by
Ashworth and Helleday [213,214]. They combined chemical
inhibition of the base excision repair factor Poly(ADP-ribose) poly-
merase (PARP) in the context of breast cancer where patients are
defective in recombination mediator BRCA2. The great sensitiza-
tion observed in these cells is a consequence of blocked repair of
ssDNA breaks by PARP inhibition. These are converted to dsDNA
breaks as a result of stalled replication forks that cannot be
repaired in these recombination-deﬁcient cells lines. Accordingly,
other HR-deﬁcient cells are also sensitive to PARP inhibition
[215,216], thus suggesting their broader use.
Numerous other examples of SLS are now being reported,
including sensitization of FA cells to ATM inhibitors [217]. Regard-
ing the nucleases involved in HR, ERCC1-deﬁcient cancer cells are
synthetically lethal with ATR [218]. FEN1 depletion or inhibition
has been shown to cause synthetic lethality with CDC4 and
MRE11 mutations in cancer cell lines [219]. FEN1-depletion also
results in SLS of RAD54B-deﬁcient colorectal cells [220]. Further-
more, SLX1 and MUS81 complexes are synthetic lethal in the
absence of BLM, thus conﬁrming evolutionary conservation of the
processing of replication-induced intermediates [19,37].
2452 Z. Bartosova, L. Krejci / FEBS Letters 588 (2014) 2446–2456While whole-genome synthetic lethality screens in yeast have
helped to characterize the genetic interaction network, to conduct
similar studies in humans is technically more demanding. Never-
theless, identiﬁcation of SLS genes will not only help to understand
redundancy and complexity of repair pathways as potential targets
and consequently to select more powerful patient-speciﬁc treat-
ments, it also will allow to circumvent resistance mechanisms. In
any case, detailed biochemical characterization of potential targets,
design of throughput screening methods, as well as identiﬁcation
of reliable biomarkers are essential for future clinical trials and
applications.
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